Is BARD1 p.Leu585Pro (c.1754T>C) pathogenic?

BARD1 p.Leu585Pro (c.1754T>C) is classified Uncertain significance in BARD1 (ClinVar, Multiple submitters, 10 submitters; last evaluated 2025-06-05). AlphaMissense: likely pathogenic (0.9523); Very rare (popmax 0.00136%, nfe); Associated with BARD1-related cancer predisposition.

What condition is associated with BARD1 p.Leu585Pro (c.1754T>C)?

BARD1 p.Leu585Pro (c.1754T>C) is associated with BARD1-related cancer predisposition, hereditary neoplastic syndrome, hereditary breast carcinoma (ClinVar).

How common is BARD1 p.Leu585Pro (c.1754T>C) in the general population?

BARD1 p.Leu585Pro (c.1754T>C) is very rare (popmax 0.00136%, nfe) (gnomAD).

What do computational predictors say about BARD1 p.Leu585Pro (c.1754T>C)?

AlphaMissense predicts likely pathogenic (score 0.9523) — an in-silico prediction, not a clinical call.

BARD1 p.Leu585Pro

c.1754T>C · rs786201905 · VCV185067

Uncertain significance Multiple submitters

Classification

Uncertain significance

ClinVar

Review

Multiple submitters ★★☆☆

ClinVar · 10 submitters

AlphaMissense

likely pathogenic

0.9523 · ACMG-weighted

gnomAD v4.1

Rare

very rare (popmax 0.00136%, nfe)

Missense predictors

3/3 damaging

AlphaMissense, REVEL, SaProt

Conditions

BARD1-related cancer predisposition

Computational evidence

Protein change
AlphaMissense	0.9523	likely pathogenic · top 3% in BARD1
REVEL	0.871	moderately pathogenic-leaning
SaProt	LLR -14.15	damaging
⇒ AlphaMissense, REVEL and SaProt all call this damaging.
Splicing
SpliceAI	—	not assessed · no allele here is in the release
Constraint at this position
Conservation	phyloP 11	GERP 1.9, phastCons 1
Regional constraint	o/e 1.06	unconstrained · MANE · 81 kb · p 0.077 · regional, not allelic
Overall
CADD	27.4	PHRED · no single calibrated threshold — expert panels disagree

ClinVar classifies this uncertain; the computational predictors unanimously lean damaging — a triage signal, not a reclassification

AlphaMissense carries the ACMG weight for missense; REVEL and SaProt are independent agreement signals.

Population frequency

gnomAD v4.1 · exomes + genomes

Grpmax group 0.00136% European (non-Finnish) · 16/1,179,968 alleles

Filtering AF 0.000803% ClinGen BA1/BS1 input FAF95, joint · FAF99 0.00065%

Overall 0.00109% 16/1,461,788 alleles · very rare

Rarity supports pathogenicity (ACMG PM2); frequency above a disease-specific BA1/BS1 threshold argues against it. A variant frequent in one ancestry group can be near-absent in others, so a single global figure can mislead.

Variant & gene context

Gene: BARD1
Protein: p.Leu585Pro
Coding: c.1754T>C
MANE Select: NM_000465
dbSNP: rs786201905
Type: single nucleotide variant
Location: chr2:214745778 (GRCh38)
Gene constraint: LOEUF 1.087 · pLI <0.01 · ClinGen HI 3/3 (gnomAD)
Structure: AlphaFold pLDDT 64.82 · 11 PDB
Residue 585: the brct 1 domain; an α-helix

Full BARD1 gene report on Sugi Atlas → Gene function, pathways, protein structure, interactions & more

Disease context

Also linked: hereditary neoplastic syndrome hereditary breast carcinoma

Similar variants

BARD1 p.Leu585Arg Uncertain significance ★★ ⚠ same residue
BARD1 p.Leu585Val Uncertain significance ★★ ⚠ same residue
BARD1 p.Leu585= Benign/Likely benign ★★ same residue
BARD1 p.Leu585Ile Uncertain significance ★ ⚠ same residue
BARD1 c.1314+1G>A Pathogenic/Likely pathogenic ★★ same condition
BARD1 c.1314+1G>T Likely pathogenic ★★ same condition
BARD1 c.1396-1G>A Likely pathogenic ★★ same condition
BARD1 c.1396-1G>C Likely pathogenic ★★ same condition

Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →

Cite Sugi Variant

Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/bard1-p-leu585pro (accessed [today's date]).

Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown